Bioasis Technologies (OTCMKTS:BIOAF) & Rafael (NYSE:RFL) Head to Head Contrast

Bioasis Technologies (OTCMKTS:BIOAF) and Rafael (NYSE:RFL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Profitability

This table compares Bioasis Technologies and Rafael’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioasis Technologies	N/A	N/A	N/A
Rafael	-2,846.60%	-37.27%	-31.02%

Valuation & Earnings

This table compares Bioasis Technologies and Rafael”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioasis Technologies	N/A	N/A	N/A	N/A	N/A
Rafael	$1.16 million	59.66	-$30.52 million	($0.79)	-1.69

Bioasis Technologies has higher earnings, but lower revenue than Rafael.

Insider and Institutional Ownership

11.3% of Rafael shares are held by institutional investors. 32.9% of Rafael shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Bioasis Technologies and Rafael, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioasis Technologies	0	0	0	0	0.00
Rafael	1	0	0	0	1.00

Given Bioasis Technologies’ higher probable upside, equities research analysts clearly believe Bioasis Technologies is more favorable than Rafael.

Risk and Volatility

Bioasis Technologies has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Rafael has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.

Summary

Rafael beats Bioasis Technologies on 5 of the 9 factors compared between the two stocks.

About Bioasis Technologies

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

About Rafael

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.